Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies

Mona H Ismail1, Massimo Pinzani21Department of Internal Medicine, Division of Gastroenterology, King Fahad University Hospital, Al-Khobar, Saudi Arabia; 2Dipartimento di Medicina Interna Center for Research, High Education and Transfer, Universit&agrave; degli Studi di Firenze, Florence, Ita...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ismail MH, Pinzani M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/14387ca6c1a342c2a360002dbe44a264
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:14387ca6c1a342c2a360002dbe44a264
record_format	dspace
spelling	oai:doaj.org-article:14387ca6c1a342c2a360002dbe44a2642021-12-02T07:14:35ZReversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies1179-1535https://doaj.org/article/14387ca6c1a342c2a360002dbe44a2642011-07-01T00:00:00Zhttp://www.dovepress.com/reversal-of-hepatic-fibrosis-pathophysiological-basis-of-antifibrotic--a7790https://doaj.org/toc/1179-1535Mona H Ismail1, Massimo Pinzani21Department of Internal Medicine, Division of Gastroenterology, King Fahad University Hospital, Al-Khobar, Saudi Arabia; 2Dipartimento di Medicina Interna Center for Research, High Education and Transfer, Universit&agrave; degli Studi di Firenze, Florence, ItalyAbstract: Chronic liver injuries of different etiologies eventually lead to fibrosis, a scarring process associated with increased and altered deposition of extracellular matrix in the liver. Progression of fibrosis has a major worldwide clinical impact due to the high number of patients affected by chronic liver disease which can lead to severe complications, expensive treatment, a possible need for liver transplantation, and death. Liver fibrogenesis is characterized by activation of hepatic stellate cells and other extracellular matrix producing cells. Liver fibrosis may regress following specific therapeutic interventions. Other than removing agents causing chronic liver damage, no antifibrotic drug is currently available in clinical practice. The extent of liver fibrosis is variable between individuals, even after controlling for exogenous factors. Thus, host genetic factors are considered to play an important role in the process of liver scarring. Until recently it was believed that this process was irreversible. However, emerging experimental and clinical evidence is starting to show that even cirrhosis in its early stages is potentially reversible.Keywords: liver fibrosis, cirrhosis, fibrogenesis, antifibrotic agentsIsmail MHPinzani MDove Medical PressarticleDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol 2011, Iss default, Pp 69-80 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Diseases of the digestive system. Gastroenterology RC799-869 Ismail MH Pinzani M Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
description	Mona H Ismail1, Massimo Pinzani21Department of Internal Medicine, Division of Gastroenterology, King Fahad University Hospital, Al-Khobar, Saudi Arabia; 2Dipartimento di Medicina Interna Center for Research, High Education and Transfer, Universit&agrave; degli Studi di Firenze, Florence, ItalyAbstract: Chronic liver injuries of different etiologies eventually lead to fibrosis, a scarring process associated with increased and altered deposition of extracellular matrix in the liver. Progression of fibrosis has a major worldwide clinical impact due to the high number of patients affected by chronic liver disease which can lead to severe complications, expensive treatment, a possible need for liver transplantation, and death. Liver fibrogenesis is characterized by activation of hepatic stellate cells and other extracellular matrix producing cells. Liver fibrosis may regress following specific therapeutic interventions. Other than removing agents causing chronic liver damage, no antifibrotic drug is currently available in clinical practice. The extent of liver fibrosis is variable between individuals, even after controlling for exogenous factors. Thus, host genetic factors are considered to play an important role in the process of liver scarring. Until recently it was believed that this process was irreversible. However, emerging experimental and clinical evidence is starting to show that even cirrhosis in its early stages is potentially reversible.Keywords: liver fibrosis, cirrhosis, fibrogenesis, antifibrotic agents
format	article
author	Ismail MH Pinzani M
author_facet	Ismail MH Pinzani M
author_sort	Ismail MH
title	Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
title_short	Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
title_full	Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
title_fullStr	Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
title_full_unstemmed	Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
title_sort	reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/14387ca6c1a342c2a360002dbe44a264
work_keys_str_mv	AT ismailmh reversalofhepaticfibrosispathophysiologicalbasisofantifibrotictherapies AT pinzanim reversalofhepaticfibrosispathophysiologicalbasisofantifibrotictherapies
_version_	1718399502151319552

Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies

Ejemplares similares